- Home
- ELVN vs BY Comparison
ELVN vs BY Comparison
Compare ELVN & BY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- BY
- Stock Information
- Founded
- ELVN 2016
- BY 1914
- Country
- ELVN United States
- BY United States
- Employees
- ELVN N/A
- BY N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- BY Major Banks
- Sector
- ELVN Health Care
- BY Finance
- Exchange
- ELVN Nasdaq
- BY Nasdaq
- Market Cap
- ELVN 1.1B
- BY 1.2B
- IPO Year
- ELVN 2020
- BY 2017
- Fundamental
- Price
- ELVN $21.86
- BY $29.13
- Analyst Decision
- ELVN Strong Buy
- BY Hold
- Analyst Count
- ELVN 5
- BY 3
- Target Price
- ELVN $37.80
- BY $32.00
- AVG Volume (30 Days)
- ELVN 220.2K
- BY 120.4K
- Earning Date
- ELVN 03-13-2025
- BY 01-23-2025
- Dividend Yield
- ELVN N/A
- BY 1.23%
- EPS Growth
- ELVN N/A
- BY 3.00
- EPS
- ELVN N/A
- BY 2.75
- Revenue
- ELVN N/A
- BY $379,856,000.00
- Revenue This Year
- ELVN N/A
- BY N/A
- Revenue Next Year
- ELVN N/A
- BY $3.24
- P/E Ratio
- ELVN N/A
- BY $10.69
- Revenue Growth
- ELVN N/A
- BY 7.52
- 52 Week Low
- ELVN $10.90
- BY $19.70
- 52 Week High
- ELVN $30.03
- BY $32.89
- Technical
- Relative Strength Index (RSI)
- ELVN 44.27
- BY 53.74
- Support Level
- ELVN $21.45
- BY $27.87
- Resistance Level
- ELVN $22.82
- BY $29.02
- Average True Range (ATR)
- ELVN 1.55
- BY 0.62
- MACD
- ELVN 0.00
- BY 0.17
- Stochastic Oscillator
- ELVN 32.63
- BY 73.71
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium-sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to our customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.